Food, Drugs, Healthcare, Life Sciences

Insilico Medicine has reported that Rentosertib, an AI-discovered clinical candidate for idiopathic pulmonary fibrosis, demonstrates effectiveness in reversing the predicted biological age of IPF patients according to six independent proteomic aging clocks. The molecule's dual-purpose approach—targeting both a diagnosable disease and biological aging simultaneously—may open new pathways for anti-aging therapies...

Congressional leaders are pressing federal agencies to demonstrate how they balance advancing U.S. biotechnology research with protecting against emerging biosecurity threats. The inquiry focuses on whether agencies have implemented key recommendations from a national security commission and what additional resources they need to maintain American leadership in this rapidly evolving field.

The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.

Bergeson & Campbell provides comprehensive coverage of federal regulatory developments affecting chemicals, pesticides, and related products, including EPA's latest TSCA risk evaluations, FIFRA pesticide updates, and emerging policy initiatives across environmental and chemical safety programs.

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.

InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.

Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy.

Insilico Medicine has reported that Rentosertib, an AI-discovered clinical candidate for idiopathic pulmonary fibrosis, demonstrates effectiveness in reversing the predicted biological age of IPF patients according to six independent proteomic aging clocks. The molecule's dual-purpose approach—targeting both a diagnosable disease and biological aging simultaneously—may open new pathways for anti-aging therapies...

The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.